Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

5 clusters · 9 sources · 22 days · First seen about 2 months ago · Last updated 28 days ago

Tempus AI earnings, Personalis acquisition, and market shift

Overview

In early August 2026, Tempus AI reported a 22% year-over-year increase in second-quarter revenue to $382.5 million, driven by growth in both diagnostics and data-applications segments. The company announced FDA approval for its tumor-only xT CDx test and the launch of a whole-genome offering for rare disease, while institutional investors, including Avidity Partners Management LP, added or increased stakes. A few days later, the firm disclosed that CEO Ryan Fukushima and director David Epstein each sold shares under pre-arranged Rule 10b5-1 plans. Fukushima sold 23,818 shares on August 3 for approximately $1.1 million, while Epstein sold 370 shares for roughly $16,058. Both executives retained substantial holdings following these transactions. Subsequent analysis of the second-quarter results revealed that while the company posted its first quarterly profit of $5.64 million, the net income was primarily driven by non-operating income. Specifically, approximately $103 million in “other income”—largely consisting of $98.47 million in unrealized gains from stock holdings such as Recursion and Personalis—offset an operating loss of $75.91 million. Despite the reliance on these non-operating gains, analysts maintained a median price target of approximately $66.00. By mid-August, investor sentiment shifted upward following a $1.5 billion agreement to acquire Personalis. This acquisition is intended to integrate advanced genetic analysis and sequencing capabilities, with plans to handle gene sequencing for a personalized cancer vaccine being developed by Moderna and Merck, pending FDA approval. Analysts view this as a potential new “pharma services” revenue stream. Consequently, BTIG Research upgraded the stock, raising its price target from $70 to $80 while maintaining a “buy” rating, coinciding with increased trading volume and a 57% rise in call option volume. By late August, Tempus AI shares surged 39.5% in a single week, fueled by positive Phase 3 clinical trial results from Merck and Moderna.

Entities

Tempus AI · Personalis · Merck · Moderna · David Epstein

Timeline

28 days ago

[BUSINESS] 4 sources
Tempus AI shares surge following Merck and Moderna cancer vaccine trial results
Tempus AI stock rose nearly 40% following successful Phase 3 trial results for a Merck and Moderna cancer vaccine, validating technology from Personalis, which Tempus is set to acquire.
about 1 month ago

[BUSINESS] 2 sources
Tempus AI shares rise following BTIG analyst upgrade and Personalis deal
Tempus AI shares rose following a BTIG Research upgrade to an $80 price target, driven by optimism over its $1.5 billion acquisition of Personalis and potential sequencing roles for cancer vaccines.
about 1 month ago

[BUSINESS] 2 sources
Tempus AI reports first quarterly profit driven by non-operating income
Tempus AI reported its first quarterly profit in Q2 2026, driven by $103 million in non-operating income and unrealized gains, despite an operating loss in its core AI healthcare business.
about 1 month ago

[BUSINESS] 2 sources
Tempus AI CEO and Director Disclose August Share Sales
Tempus AI CEO Ryan Fukushima sold 23,818 shares for $1.1 million and Director David Epstein sold 370 shares for $16,000 on Aug 3, both under Rule 10b5‑1 plans, reducing their holdings.
about 2 months ago

[BUSINESS] 2 sources
Tempus AI posts 22% Q2 revenue rise, secures new institutional stake
Tempus AI posted 22% Q2 revenue growth to $382.5 M, GAAP net income $5.6 M and FDA approval for tumor‑only xT CDx, while Avidity Partners added a $1.1 M stake.

Sources

bitcoinethereumnews.com · cryptonomist.ch · klubkreatywnych.pl · knausport.nl · mommygearest.com · newsable.asianetnews.com · otravel.com · stocknews.com · tmtpost.com

This summary has been updated 3 times: see revision history